Novartis AG (NOVN) Receives Consensus Rating of “Hold” from Analysts

Novartis AG (VTX:NOVN) has received an average recommendation of “Hold” from the fifteen research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is CHF 86.10.

A number of research analysts recently commented on the company. Deutsche Bank AG set a CHF 83.50 price target on Novartis AG and gave the stock a “neutral” rating in a report on Wednesday, November 8th. Morgan Stanley set a CHF 88 price target on Novartis AG and gave the stock a “buy” rating in a report on Tuesday, November 14th. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on Novartis AG and gave the stock a “neutral” rating in a report on Tuesday, October 17th. Jefferies Group LLC set a CHF 100 price target on Novartis AG and gave the stock a “buy” rating in a report on Monday, October 16th. Finally, set a CHF 90 price target on Novartis AG and gave the stock a “buy” rating in a report on Thursday, October 12th.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/novartis-ag-novn-receives-consensus-rating-of-hold-from-analysts.html.

Novartis AG (VTX:NOVN) opened at CHF 83.30 on Monday. Novartis AG has a 52 week low of CHF 67.80 and a 52 week high of CHF 85.40.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply